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Background-—Heterozygous loss of function mutations in the KCNK3 gene cause hereditary pulmonary arterial hypertension
(PAH). KCNK3 encodes an acid-sensitive potassium channel, which contributes to the resting potential of human pulmonary artery
smooth muscle cells. KCNK3 is widely expressed in the body, and dimerizes with other KCNK3 subunits, or the closely related,
acid-sensitive KCNK9 channel.
Methods and Results-—We engineered homomeric and heterodimeric mutant and nonmutant KCNK3 channels associated with
PAH. Using whole-cell patch-clamp electrophysiology in human pulmonary artery smooth muscle and COS7 cell lines, we
determined that homomeric and heterodimeric mutant channels in heterozygous KCNK3 conditions lead to mutation-specific
severity of channel dysfunction. Both wildtype and mutant KCNK3 channels were activated by ONO-RS-082 (10 lmol/L), causing
cell hyperpolarization. We observed robust gene expression of KCNK3 in healthy and familial PAH patient lungs, but no quantifiable
expression of KCNK9, and demonstrated in functional studies that KCNK9 minimizes the impact of select KCNK3 mutations when
the 2 channel subunits co-assemble.
Conclusions-—Heterozygous KCNK3 mutations in PAH lead to variable loss of channel function via distinct mechanisms.
Homomeric and heterodimeric mutant KCNK3 channels represent novel therapeutic substrates in PAH. Pharmacological and pH-
dependent activation of wildtype and mutant KCNK3 channels in pulmonary artery smooth muscle cells leads to membrane
hyperpolarization. Co-assembly of KCNK3 with KCNK9 subunits may provide protection against KCNK3 loss of function in tissues
where both KCNK9 and KCNK3 are expressed, contributing to the lung-specific phenotype observed clinically in patients with PAH
because of KCNK3 mutations. ( J Am Heart Assoc. 2017;6:e006465. DOI: 10.1161/JAHA.117.006465.)
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P ulmonary arterial hypertension (PAH) is a progressiveprimary illness of the lung, characterized by increased
pulmonary artery pressure ≥25 mm Hg, increased pulmonary
vascular resistance, right-sided heart failure, and high
mortality rates.1 Pulmonary arterial endothelial and smooth
muscle cell proliferation and excessive vasoconstriction are
pathogenetic mechanisms in PAH. Mutations in the BMPR2
gene, a component of the transforming growth factor-b
signaling pathway, account for most genetic cases of PAH,
while less frequently, mutations in other genes underlie the
disease.2
We recently identified KCNK3 as the first ion channelopa-
thy associated with PAH.3 Using exome sequencing, 6 distinct
mutations in the KCNK3 potassium channel were identified in
patients with hereditary PAH. All patients were heterozygous
at the KCNK3 gene locus, possessing 1 mutant and 1 wildtype
(WT) channel. Each of the 6 KCNK3 mutations led to loss of
channel function, and some mutant channels were function-
ally rescued by ONO-RS-082 (ONO), a phospholipase A2
inhibitor and KCNK3 activator.3
KCNK3 encodes an acid-sensitive 2-pore domain potas-
sium channel (also referred to as TASK-1), extremely sensitive
to extracellular pH, especially within the range of physiological
pH 7.4.4 Strongly inhibited by extracellular acidosis and
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hypoxia, KCNK3 regulates cellular excitability, and is thought
to contribute to hypoxic pulmonary vasoconstriction.5 The
voltage-insensitivity of KCNK3 renders the channel open
across all voltages, leading to potassium efflux from cells
expressing the channel, which contributes to the negative
resting potential. KCNK3 is widely expressed in the human
body, including in the central nervous system, heart, and
pulmonary artery smooth muscle cells (PASMCs).6,7
KCNK3 currents contribute to the PASMC resting potential
and impact pulmonary arterial tone and smooth muscle cell
growth; KCNK3 downregulation or inhibition leads to PASMC
depolarization, proliferation, and pulmonary arterial constric-
tion.5,7–9 Notably, KCNK3 downregulation was recently iden-
tified as a pathogenic hallmark of PAH in humans and in a
monocrotaline-induced pulmonary hypertension rat model,
and administration of ONO alleviated signs of pulmonary
hypertension in the animal model, further implicating KCNK3
as a therapeutic target in PAH.3,8
KCNK3 dimerizes in vivo, forming functional channels from
2 channel subunits linked together.10 Adding to the complex-
ity of KCNK3 regulation, the closely related acid-sensitive
KCNK9 channel dimerizes with KCNK3, forming KCNK9-
KCNK3 heterodimeric channels in tissues where both chan-
nels are expressed.11–15 KCNK9 is more maximally activated
at pH 7.4 than KCNK3.16,17 The channels are co-expressed in
a variety of tissues, promoting tissue-specific diversity of
channel function.
In this study, we investigate (1) mechanisms of heterozy-
gous KCNK3 loss of function mutations in PAH by studying
channel function over a broad pH range; (2) the capacity of
mutant and WT KCNK3 channels to serve as therapeutic
targets in PAH; (3) the impact of selected KCNK3 mutations
on channel function and pharmacology in physiologically
relevant heterozygous conditions; and (4) the potential role
for KCNK9 in underlying the lung-specific disease pheno-
type conferred upon patients with heterozygous KCNK3
mutations.
Methods
Data S1 include further details of materials and methods.
Study Patients
Human lung parenchymal samples were obtained from 10
control patients (failed donor lungs); 5 patients with familial
PAH; and 5 patients with congenital heart disease–associated
PAH. cDNA samples were provided by the Pulmonary
Hypertension Breakthrough Initiative.18 We were not required
to obtain informed consent. The protocol, “Studying Gene
Expression in Pulmonary Arterial and Lung Tissue in Healthy
and Diseased Samples,” (#AAAQ2454) was approved by the
Institutional Review Board at Columbia University Medical
Center. KCNK3 mutations in PAH patients were identified as
previously reported.3
Quantitative Real-Time Polymerase Chain
Reaction
The TaqMan gene expression system was used to quantify
mRNA expression (Applied Biosystems). No-template controls
lacking cDNA were included. Experiments were performed in
duplicate for each sample. Data are expressed as means of
the average cycle threshold (Ct) value of duplicates, and as
fold changes in expression (2MMCt method).
Molecular Biology
Mutations were engineered into human KCNK3 cDNA in a
pcDNA3.1+ expression vector by site-directed mutagenesis
using QuickChange (Stratagene).3 Human KCNK9 cDNA in a
pIRES-GFP and pcDNA3.1+ vector was used. Where noted,
KCNK3 constructs were tagged with a C-terminal green
fluorescent protein (GFP). Tandem-linked KCNK3-KCNK3 and
KCNK9-KCNK3 dimer constructs were engineered by joining 2
Clinical Perspective
What Is New?
• Heterozygous KCNK3 mutations associated with pulmonary
arterial hypertension result in loss of potassium channel
function by differing mechanisms, and with varying severity.
• Activation of mutant and nonmutant KCNK3 channels in a
pulmonary artery smooth muscle cell line by the phospho-
lipase A2 inhibitor, ONO-RS-082, or by extracellular alkalo-
sis, leads to graded cell hyperpolarization.
• KCNK9 heterodimerizes with mutant and nonmutant KCNK3
channel subunits, and minimizes the impact of KCNK3 loss-
of-function mutations when KCNK9 and KCNK3 co-
assembled.
What Are the Clinical Implications?
• Homodimeric and heterodimeric mutant and nonmutant
KCNK3 potassium channels represent potential therapeutic
targets in pulmonary arterial hypertension.
• The absence of KCNK9 expression in the lung may underlie
the lung-specific phenotype observed in pulmonary arterial
hypertension patients with heterozygous KCNK3 mutations.
• Developing pharmacologic agents that specifically regulate
KCNK3 activity, and an animal model to study the physi-
ological consequences of such agents, warrant further
investigation in the context of pulmonary hypertension
treatment.
DOI: 10.1161/JAHA.117.006465 Journal of the American Heart Association 2
Heterozygous KCNK3 Mutations in PAH Bohnen et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on April 2, 2019
KCNK subunits with a glycine-rich linker, subcloned into a
pcDNA3.1+ vector.
Materials
ONO-RS-082 (Enzo), ML365 (MedChem Express), ruthenium
red, and dimethylsulfoxide (Life Technologies) were purchased
commercially.
Cell Culture and Heterologous Channel
Expression
KCNK3 and KCNK9 channel constructs were expressed in
cultured human PASMC and COS7 cell lines. GFP was co-
expressed or tagged to the C-terminus of the channel as a
marker of transfection. A previously established transfection
protocol using Lipofectamine reagents was used in COS7
cells,3 with modifications to optimize efficiency in human
PASMCs (hPASMCs).
Electrophysiology
KCNK3 channel current and membrane potential changes
were recorded by whole-cell patch clamp in hPASMCs and
COS7 cells. An Axopatch 200B amplifier (Axon Instruments),
Digidata 1440A model, and pClamp 10 software were used for
recording and analysis (Molecular Devices, CA). For voltage
clamp experiments, cells were held at 80 mV and a 500-ms
voltage ramp was applied once every 3 s, with voltage
increasing linearly from 120 mV to +60 mV before return-
ing to holding. Expressed KCNK3, KCNK9, and tandem dimer
constructs were recorded. For current clamp experiments,
changes in membrane potential were recorded over time after
first applying the voltage ramp to verify stability of the patch
and expression of KCNK3 channels.
For experiments in COS7 cells, solutions were prepared
as previously reported3: pipette (internal) solution (in mmol/
L) contained: 150 KCl, 3 MgCl2, 5 EGTA, 10 HEPES,
adjusted to pH 7.2 with KOH. Bath (extracellular) solution (in
mmol/L) contained: 150 NaCl, 5 KCl, 1 MgCl2, 1.8 CaCl2,
10 HEPES adjusted to pH 6.4, 7.4, or 8.4 with NaOH. In
hPASMCs, solutions were adapted from a prior study.5
Pipette (internal) solution (in mmol/L) contained: 135 K-
methanesulphonate, 20 KCl, 2 Na2ATP, 1 MgCl2, 1 EGTA, 20
HEPES, adjusted to pH 7.2 with KOH. Bath (extracellular)
solution (in mmol/L) contained: 140.5 NaCl, 5.5 KCl, 1.5
CaCl2, 1 MgCl2, 10 glucose, 0.5 Na2HPO4, 0.5 KH2PO4, 10
HEPES, adjusted to pH 6.4, 7.4, or 8.4 with NaOH. In COS7
cells and hPASMCs, solutions at pH 5.0 contained
10 mmol/L 2-(N-morpholino)ethane sulfonic acid instead of
HEPES. Solutions at pH 10.4 contained 10 mmol/L Tris-
Base instead of HEPES.
Statistical Analyses
Graphic analysis was performed with Origin 7.0 and 9.0
(Microcal Software, Northampton, MA). pClamp 10 software
was used for electrophysiological analysis. Data are reported
as meansSEM, based on n observations. Student t tests and
1-way ANOVA with post hoc Tukey tests were applied as
indicated, and significant differences were determined based
on P<0.05. Statistical tests were performed using Origin and
Excel software (Microsoft, Bellevue, WA).
Results
Functional Characterization of KCNK3 Variants
Identifies a Unique Acid-Sensing Phenotype
We previously identified 6 loss of function mutations in
KCNK3 causing PAH.3 Given the extreme sensitivity of KCNK3
channels to extracellular pH changes within the physiological
pH range, here we investigated the mechanistic basis of loss
of channel function focusing on possible mutation-induced
changes in the pH dependence of the expressed channels. WT
or mutant KCNK3 channels were expressed in COS7 cells, and
a whole-cell voltage ramp was applied across a physiological
voltage range (Figure 1A, top). As expected for WT KCNK3
channels, we observed appreciable K+ current at physiological
extracellular pH 7.4; inhibition of current by acidosis, pH 6.4;
and activation of current by alkalosis, pH 10.4 (Figure 1A and
1B).4
Compared with WT KCNK3 channels, all 6 PAH-associated
mutant KCNK3 channels exhibited loss of function at pH 7.4
and pH 10.4 (Figure 1B), with 1 notable exception: V221L
KCNK3 conferred loss of function at physiological pH 7.4, with
recovery of function observed at alkalotic pH 10.4 (Figure 1A
and 1B). Given its unique alteration in pH-dependent regula-
tion and readily discernible robust current activity in alkalotic
conditions, V221L KCNK3 served as a model KCNK3 mutant
to study in more physiologic conditions, using cultured
hPASMCs.
Cultured hPASMCs Provide a Physiological
Platform for KCNK3 Expression
KCNK3 currents contribute to the resting potential of native
PASMCs, and the downregulation or inhibition of KCNK3
causes PASMC depolarization, excessive proliferation, and
pulmonary arterial constriction.5,7–9 Cultured PASMCs have
been used previously to study overexpressed potassium
channel activity, regulation, and pharmacology in the context
of PAH.19,20 We adapted this approach to test the hypothesis
that both WT and mutant (eg, V221L) KCNK3 channels
represent therapeutic targets in PAH (Figure 2).
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As loss of function could result from lack of KCNK3
expression, we first engineered a C-terminal GFP-tagged
KCNK3 channel (KCNK3-GFP, Figure 2A) and screened its
function in COS7 cells. We observed a similar pH dependence
for KCNK3-GFP versus KCNK3, as well as a significant
increase in current density (pA/pF, measured at 60 mV) for
KCNK3-GFP (Figure 2B). In voltage-clamp experiments, ONO
10 lmol/L activated KCNK3-GFP with similar efficacy to
KCNK3 channels (Figure 2C; and compare with KCNK3
activation previously reported3). The recently developed
KCNK3 inhibitor, ML365 10 lmol/L,21,22 produced robust
inhibition of KCNK3-GFP currents (Figure 2C). Mean current
densities (pA/pF) in response to the drugs are summarized in
Figure 2C, measured at 50 mV to minimize interference of
background ionic currents, including minimizing nonselective
effects of ONO observed at more depolarized potentials.
The use of KCNK3-GFP thus did not appreciably change
KCNK3 function or pharmacology, while providing the advan-
tage of increased current density. Next, KCNK3-GFP was
expressed in cultured hPASMCs, identified by green fluores-
cence, and produced similar current density (pA/pF at
60 mV) compared with KCNK3-GFP expression in COS7 cells
(Figure 2D).
Loss of native KCNK3 expression was previously demon-
strated in cultured PASMCs,23 and confirmed functionally in
our system of cultured hPASMCs by applying ML365
10 lmol/L in nontransfected hPASMCs, and observing no
significant effect on cell currents (Figure 2E, 2F, and S1B).
The lack of effect of ML365 in nontransfected cells highlights
its strong selectivity for KCNK3 inhibition when KCNK3 is
expressed. In comparison, KCNK3-GFP expression in
hPASMCs produced robust channel activity, inhibited by
ML365 10 lmol/L (Figure 2G, 2H, S1B, and S1C). We thus
developed a platform to compare the relative impact of
expressed mutant versus WT KCNK3 channels on hPASMC
membrane potential, and the effect of KCNK3 pharmacolog-
ical agents in a more physiological environment (Figure 3).
Activation of PAH-Associated Mutant KCNK3
Channels in hPASMCs
KCNK3-GFP expression in hPASMCs produced a consistent
pH dependence of expressed channel activity compared with
expression in COS7 cells (Figure 3A and 3B). We recorded
membrane potentials in cells expressing KCNK3-GFP at
physiological pH 7.4, upon channel activation by pH 10.4,
and upon inhibition by pH 6.4. A sample current clamp trace
(Figure 3C) reveals a resting potential of 68 mV at pH 7.4,
hyperpolarization to 70 mV at pH 10.4, and depolarization
to 44 mV at pH 6.4 (summarized in Figure S1A).
Next, we determined the relative impact of pharmacolog-
ical activation and inhibition of KCNK3 in hPASMCs express-
ing WT or V221L KCNK3-GFP. A recording of a cell expressing
WT KCNK3-GFP (Figure 3D) demonstrates a resting potential
of 62 mV at physiological pH 7.4; hyperpolarization by ONO
10 lmol/L to 73 mV; and depolarization to 51 mV upon
Figure 1. Pulmonary arterial hypertension (PAH)-
associated mutant KCNK3 channels demonstrate
mutation-specific severity of loss of function,
across a broad pH range in COS7 cells. A, Typical
voltage clamp recordings of wildtype (WT, top) and
V221L (bottom) KCNK3. Sample current traces at
pH 6.4 (blue), 7.4 (black), and 10.4 (red) are shown.
A voltage ramp (top) was applied, 120 mV to
+60 mV over 0.5 s, every 3 s, from a holding
potential of 80 mV for all voltage clamp record-
ings in this study. B, Summary of current density
(pA/pF at 60 mV) of cells expressing WT or one of
the PAH-associated mutant KCNK3 channels (n=3–
9 cells at pH 6.4; n=6–33 cells at pH 7.4; n=6–32
cells at pH 10.4). Bars show meanSEM. *P<0.05
at pH 7.4; #P<0.05 at pH 10.4, for the comparison
of WT and each KCNK3 mutant channel by 1-way
ANOVA (P<0.05) and post hoc Tukey test.
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co-application of ML365 10 lmol/L. By comparison, a
recording of a cell expressing V221L KCNK3-GFP (Figure 3E)
reveals a resting potential of 40 mV at physiological pH 7.4;
hyperpolarization by ONO 10 lmol/L to 61 mV; and
depolarization to 33 mV upon co-application of ML365
10 lmol/L. A summary of resting potentials, and responses
Figure 2. KCNK3 expression platform in human pulmonary artery smooth muscle cells (hPASMCs). A,
KCNK3, tagged with GFP at the C-terminus, was engineered (KCNK3-GFP). B, KCNK3-GFP (gray curve) vs
KCNK3 (black curve) expression in COS7 cells across a broad pH range, with current normalized to max
current at pH 10.4 (n=9–25 cells per pH data point for KCNK3; n=9–12 cells for KCNK3-GFP; fitted by the
Hill equation. C, KCNK3-GFP is activated by ONO-RS-082 (ONO) 10 lmol/L (red trace, left) and inhibited by
ML365 10 lmol/L (blue trace, right), under voltage-clamp shown in COS7 cells. Predrug (control, black
traces) and drug conditions are at pH 7.4. Bar graphs (bottom) show percent change in current at 50 mV
after ONO (n=8 cells) or ML365 (n=12 cells) application, compared with control. D, Cultured hPASMCs (left,
top) expressing KCNK3-GFP fluoresce green (left, bottom). Bar graph (right) shows KCNK3-GFP current
activity at pH 7.4 (pA/pF at 60 mV) in hPASMCs (gray, n=20 cells) vs COS7 cells (black, n=26 cells). E,
Background hPASMC current at pH 7.4 (control, gray trace), and after application of ML365 10 lmol/L
(blue trace). F, Sample ML365 time course of action in control and drug conditions, measured at 50 mV,
from a starting current amplitude of 6 pA indicated by the arrow. G, Current from hPASMC expressing
KCNK3-GFP is shown at pH 7.4 (control, gray trace), and in ML365 10 lmol/L (blue trace). H, Sample
ML365 time course of action in control and drug conditions, measured at 50 mV, from a starting current
amplitude of 412 pA indicated by the arrow. Horizontal dashed line is drawn at the starting level of current
in control solution. Bar graphs show meanSEM. *P<0.05 by the paired (B) and unpaired (C) Student t test.
N.S. indicates no significant difference.
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to ONO 10 lmol/L, and to ML365 10 lmol/L, is shown in
Figure 3F, for WT and V221L KCNK3-GFP. In each condition,
V221L KCNK3-GFP responses are significantly different from
WT.
KCNK3 Heterodimeric Channels Are Functional
Reporters of KCNK3 Heterozygosity
After demonstrating that PAH-associated mutant KCNK3
channels are potential therapeutic targets in hPASMCs, we
investigated the consequence of heterozygosity on channel
function more closely. All patients harboring PAH-associated
KCNK3 mutations in our study are heterozygous at the KCNK3
locus, possessing 1 mutant and 1 WT KCNK3 channel
subunit.3 KCNK3 is known to dimerize, forming functional
channels from 2 subunits joined together.10 For heterozygous
expression, net current is therefore a result of 3 populations
of channels: homodimers of WT or mutant KCNK3, and
heterodimers with 1 of each subunit. We engineered tandem-
linked KCNK3 dimers by joining 2 KCNK3 subunits with a
glycine-rich linker; by forcing assembly of mutant and/or WT
KCNK3 subunits to one another, we assessed function of
discrete proportions of channels (ie, heterodimers) that form
in a heterozygous patient (Figure 4).
We tested function of mutant heterodimeric channels
containing the V221L mutation. Figure 4A and 4B depict the
engineered WT KCNK3 homodimer and WTV221L mutant
KCNK3 heterodimer, respectively, with sample current traces
shown at extracellular pH 6.4, 7.4, and 10.4 from voltage
clamp experiments. Figure 4C summarizes current density
measurements (pA/pF at 60 mV) for each dimer. Significant
loss of function was observed at pH 7.4 for WTV221L
heterodimeric channels. We recorded V221L-containing
KCNK3 function over a broad pH range, 5.0 through 10.4,
and notably, WTV221L KCNK3 produced an intermediate
rightward shift in pH dependence (Figure 4D, blue curve), with
intermediate channel activity at physiological pH 7.4, com-
pared with WT KCNK3 (Figure 4D, black curve), and V221L
KCNK3 (Figure 4D, red curve), for which we observed an
extreme rightward shift in pH dependence.
The dominant-negative impact of KCNK3 heterozygosity on
channel function was quantified further. Figure 4E shows a
scatterplot of individual voltage clamp recordings (n=16–33
cells per condition: WT homomeric, V221L homomeric,
WTV221L heterodimeric, and WT+V221L monomeric sub-
unit co-expression), with each data point representing the
current recorded at physiological pH 7.4, normalized to
maximal current at pH 10.4, measured at 60 mV. Loss of
function was observed for all conditions containing V221L
mutant channels (homomeric V221L, WTV221L heterodi-
mer, and co-expression of WT+V221L). Importantly, we
observed greater variation in current when co-expressing
WT+V221L channels compared with WTV221L heterodimer
expression. The co-expression population, an equal 1:1
stoichiometric ratio of WT to V221L KCNK3 channel
expressed, includes randomly assembled homodimers of WT
KCNK3, V221L KCNK3, and WTV221L heterodimers and
Figure 3. Robust response of KCNK3 channels to pH changes
and pharmacological modulators in human pulmonary artery
smooth muscle cells (hPASMCs). A, Voltage clamp recording of
KCNK3-GFP expressed in hPASMCs at pH 6.4 (blue), pH 7.4
(black), and pH 10.4 (red). B, KCNK3-GFP expression in hPASMCs
(gray curve) vs COS7 cells (black curve) across a broad pH range,
with current normalized to max current at pH 10.4 (n=9–12 cells
per pH data point in COS7; n=2–6 cells per pH data point in
hPASMCs; fitted by the Hill equation). C, Current clamp recording
of wildtype (WT) KCNK3-GFP, with changes in membrane potential
(mV) measured at pH 6.4 (blue), pH 7.4 (black), and pH 10.4 (red).
D, Current clamp recording of WT KCNK3-GFP (red trace),
showing changes in membrane potential (mV) upon application
of ONO-RS-082 (ONO), ONO+ML365, or pH 8.4. E, Current clamp
recording of V221L KCNK3-GFP (blue trace), showing changes in
membrane potential (mV) upon application of ONO, or
ONO+ML365. F, Current clamp summary of WT (red) and
V221L (blue) KCNK3-GFP for resting potential, ONO, and
ONO+ML365 conditions (n=3–11 cells per condition). Drugs
applied at a concentration of 10 lmol/L in all experiments. Data
plots represent meansSEM. *P<0.05 by the unpaired Student
t test.
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therefore fully recapitulates heterozygous conditions. The
minimal variation in current in the WT homomer, V221L
homomer, and WTV221L heterodimer lanes in Figure 4E
supports the notion that we dissected current activity of
discrete proportions of formed channels that would assemble
in a heterozygous patient.
Pharmacological Activation of Heterodimeric
Mutant KCNK3 Channels
In voltage clamp recordings, WT KCNK3 homodimers (Fig-
ure 5A) and WTV221L mutant heterodimers (Figure 5B)
were activated by ONO 10 lmol/L (shown in red), and
inhibited by ML365 10 lmol/L (shown in blue), in voltage-
clamp recordings. PAH-associated KCNK3 heterodimeric
channels thus represent therapeutic targets in PAH, suscep-
tible to pharmacological recovery. Patients with PAH caused
by heterozygous KCNK3 mutation therefore possess a
significant proportion of assembled KCNK3 channels (WT
and mutant) that, dependent on the mutation, represent viable
targets for treatment.
As shown previously,3 cells expressing T8K or E182K
KCNK3 channels are modulated by ONO 10 lmol/L. Impor-
tantly, ONO is not a KCNK3-specific activator and produces
variable responses in the presence and absence of KCNK3.
As such, it is difficult to quantify the drug’s effect, especially
in the setting of loss-of-function KCNK3 mutant channels
that produce small currents at baseline (Figure S2A through
S2C), yet we observed variable activation of current of T8K-,
E182K-, and V221L-based KCNK3 constructs in the presence
of ONO.
In addition to the WTV221L KCNK3 heterodimer, the WT-
E182K KCNK3 heterodimer responds robustly to current
activation by ONO 10 lmol/L, suggesting that a significant
population of channels (WT and mutant heterodimeric) in
patients with heterozygous KCNK3 mutations respond to
pharmacological activation (Figure S2D).
KCNK3 and KCNK9 Form Functional
Heterodimeric Channels
To elucidate the broader impact of KCNK3 heterozygosity on
channel function, we investigated the interactions of KCNK3
with a closely related acid-sensitive, 2-pore domain potassium
channel, KCNK9 (Figure 6A, top). Previous reports have
shown that KCNK3 heterodimerization with KCNK9 results
in functional channels consisting of 1 KCNK3 subunit and 1
KCNK9 subunit.11–15 We engineered the first known tandem-
linked human KCNK9-KCNK3 heterodimer (Figure 6B, top).
The true dimeric assembly of KCNK9 with KCNK3 to form
KCNK9-KCNK3 heterodimers was confirmed by ruthenium red
(RR) sensitivity analysis: KCNK9 was previously shown to be
inhibited by RR (10 lmol/L), while KCNK9-KCNK3 hetero-
dimers and KCNK3 channels were not inhibited by RR
10 lmol/L as KCNK3-containing channels lack a necessary
Figure 4. Tandem-linked KCNK3 heterodimeric channels are
functional reporters of KCNK3 heterozygosity. A and B, KCNK3
dimers were engineered by interconnecting 2 KCNK3 subunits
with a glycine-rich linker. The wildtype (WT) KCNK3 homodimer
(A) and the WTV221L KCNK3 heterodimer (B) are depicted, with
sample voltage clamp recordings for each condition. Current
traces at pH 6.4 (blue), 7.4 (black), and 10.4 (red) are shown. C,
Summary of current densities (pA/pF at 60 mV) at pH 6.4, 7.4,
and 10.4 (n=4–16 cells per pH bar). D, KCNK3 current activity is
depicted for WT (black curve), V221L (red curve), and WTV221L
heterodimer (blue curve), at extracellular pH 5.0 through 10.4,
with current normalized to max current at pH 10.4 (n=5–33 cells
per pH value plotted; fitted by the Hill equation). E, Scatterplot of
current at pH 7.4 normalized to current at pH 10.4, for WT,
V221L, WTV221L heterodimer, and WT+V221L co-expression.
Each dot represents an independent cell recording. Mean current
in each condition is displayed at the horizontal line (n=16–33 cells
per condition, measured at 60 mV). Bar graphs and pH curve
values show meansSEM. *P<0.05 for the comparison of WT vs
WTV221L KCNK3 dimer conditions in panel C by the unpaired
Student t test; (E) P<0.05 for the comparison of all KCNK3
conditions, calculated by 1-way ANOVA (P<0.05) and post hoc
Tukey test.
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glutamic acid residue (E70) for RR binding and channel pore
block.11 Figure 6A (bottom) shows inhibition of KCNK9
currents by RR 10 lmol/L at pH 7.4, and Figure 6B (bottom)
shows no effect by RR 10 lmol/L on KCNK9-KCNK3
heterodimer currents. Sample drug time courses are shown
in Figure 6C and 6D, for KCNK9 and KCNK9-KCNK3, respec-
tively; RR sensitivity data are summarized in Figure 6G, for
KCNK9, KCNK3, and KCNK9-KCNK3 (and see Figure S3A
through S3C). The lack of RR sensitivity of the KCNK9-KCNK3
heterodimer confirms true assembly of KCNK9 with KCNK3,
while ensuring that the tandem dimers do not combine with
other tandem dimers to form functional channels; if this were
the case, there would have been a RR-sensitive component to
the current produced by KCNK9-KCNK3 expression, based on
assembly of KCNK9 homomeric channels.
After verifying the formation and expression of the KCNK9-
KCNK3 tandem dimer, we evaluated the pH dependence of
KCNK9-containing channels. KCNK9 has a left-shifted pH
dependence profile compared with KCNK3, rendering it more
maximally activated at physiological pH 7.4 (Figure 6E, and
compare with Figure 1A). We observed increased K+ current
activity at pH 7.4 for KCNK9-KCNK3 compared with KCNK3
homomeric channels, as expected (Figure 6F, and summa-
rized in Figure 6H).
KCNK3, But Not KCNK9, Is Expressed in Healthy
and PAH Patient Lungs
KCNK9 is thought to be co-expressed with KCNK3 in various
tissues outside of the lung, including in the central nervous
system, heart, and adrenal glands, and functional
heterodimerization of KCNK3 with KCNK9 in multiple tissues
has already been studied.6,11–13,17 KCNK3 is expressed in
hPASMCs, while KCNK9 has been reported absent from
hPASMCs.5 We performed gene expression analysis on
whole human lung tissue samples from healthy (control)
subjects, and from patients with familial PAH. KCNK3
expression was observed in lungs of control and familial
PAH patients, while no quantifiable expression of KCNK9
was observed in control or familial PAH patient lungs
(Figure 7A, top; and see Figure S3D and S3E). Therefore, of
Figure 5. Wildtype (WT) and mutant KCNK3 dimers respond to
pharmacological modulation. A, WT KCNK3 dimer (top) is
activated by ONO-RS-082 (ONO) 10 lmol/L (red trace) and
inhibited by ML365 10 lmol/L (blue trace), in current recordings
from voltage clamp experiments. Control (predrug, pH 7.4) traces
are shown in black. Bar graphs show fold change in current at
50 mV for the WT KCNK3 dimer, after ONO (red, n=4 cells) or
ML365 (blue, n=7 cells) application. B, WTV221L KCNK3
heterodimer (top) is activated by ONO 10 lmol/L (red trace),
and inhibited by ML365 10 lmol/L (blue trace), and heterodimer
channel activity was confirmed by channel activation at extracel-
lular pH 10.4 (gray dotted traces). Control (predrug, pH 7.4)
traces are shown in black. Bar graphs show fold change in current
at 50 mV for the WTV221L heterodimer, after ONO (red, n=5
cells) or ML365 (blue, n=3 cells) application. Bar graphs display
meanSEM. *P<0.05 by the paired Student t test.
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all possible KCNK3/KCNK9 channel combinations, only
KCNK3 homomeric channels would be expected to form in
human lung tissue (Figure 7A, bottom). KCNK9-KCNK3
heterodimerization adds to the complexity of KCNK3 activity,
particularly in PAH patients heterozygous at the KCNK3 gene
locus.
KCNK9 Protects Against KCNK3 Dysfunction
The lung-specific disease phenotype in patients with heterozy-
gous KCNK3 mutation, despite widespread tissue expression
of KCNK3, remains a puzzling phenomenon: Are lungs
particularly susceptible to KCNK3 loss of function due, in
part, to the absence of KCNK9? We sought to determine
whether KCNK9 can recover function of even the severe
mutant G203D KCNK3 channel, in order to test the hypoth-
esis that co-assembly of KCNK9 with KCNK3 provides
protection against heterozygous KCNK3 mutation when the
channels are co-expressed, while the absence of KCNK9 in
the lungs underlies the lung-specific phenotype in the setting
of heterozygous KCNK3 loss of function.
G203D KCNK3 disrupts the conserved “GxG” potassium
selectivity filter amino acid sequence in 1 of the channel’s 2
pore-loop domains, a region sensitive to dominant-negative
mutations.24–26 We first engineered and studied the WT-
G203D KCNK3 heterodimer (Figure 7B, left), and indeed
observed severe dominant-negative dysfunction, as the
mutant channels produced small currents across pH 6.4
through 10.4 (Figure 7B and 7C; also see Figure S4).
Next, we engineered a KCNK9-G203D KCNK3 mutant
heterodimer to determine the impact of KCNK9 assembly with
G203D KCNK3 (Figure 7B, right). We observed appreciable
pH-sensitive currents, with significantly increased current
density at physiological pH 7.4 and pH 10.4, compared with
WT-G203D KCNK3 heterodimeric channels (Figure 7B and
7C). KCNK9 thus assembles with mutant KCNK3 channels to
produce functional recovery and provide protection against
KCNK3 channel dysfunction (see also Figure S3F through S3H
for modeling heterozygous co-expression of mutant KCNK3
[eg, V221L] with KCNK9 channels).
Discussion
Our initial characterization of KCNK3 mutations associated
with PAH showed loss of function for all disease-associated
mutant channels.3 Here, we have reported 5 major findings,
summarized schematically in Figure 8. First, KCNK3 muta-
tions associated with PAH harbor mutation-specific severity of
loss of function that can occur by distinct underlying
mechanisms. Second, mutant and WT KCNK3 channels can
be pharmacologically activated in hPASMCs to cause
Figure 6. KCNK9 forms functional heterodimers with KCNK3.
A, The effect of ruthenium red (RR) 10 lmol/L (red trace) on
KCNK9 channels. Control trace (predrug, pH 7.4) shown in
gray. B, The effect of RR 10 lmol/L (red trace) on KCNK9-
KCNK3 heterodimeric channels. Control trace (predrug, pH 7.4)
shown in gray. C, Sample RR time course of action on KCNK9
in control and drug conditions, measured at 50 mV, from a
starting current amplitude of 1682 pA indicated by the arrow.
Horizontal dashed line is drawn at the starting level of current
in control solution. D, Sample RR time course of action on
KCNK9-KCNK3 heterodimers in control and drug conditions,
measured at 50 mV, from a starting current amplitude of 18
pA indicated by the arrow. E, Voltage clamp recording of
KCNK9. F, Voltage clamp recording of KCNK9-KCNK3. E and F,
sample current traces at pH 6.4 (blue), 7.4 (black), and 10.4
(red) are shown. G, Summary of RR’s effect on KCNK9, KCNK3,
and KCNK9-KCNK3, measured by percent-inhibited current at
50 mV (n=5–8 cells per condition). H, Summary of mean
current at pH 7.4 normalized to current at pH 10.4, measured
at 60 mV, for KCNK9, KCNK3, and KCNK9-KCNK3 (n=10–25
cells per condition). Bar graphs show meanSEM. *P<0.05 by
the paired Student t test for the comparison of control vs RR
(G), and * indicates significance by 1-way ANOVA (P<0.05) and
post hoc Tukey test for the comparison of KCNK9, KCNK3, and
KCNK9-KCNK3 (H).
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membrane hyperpolarization, and thus represent potential
targets for PAH treatment. Third, mutant heterodimeric
tandem-linked KCNK3 channels provide a valuable tool for
evaluating the functional impact of clinically relevant
heterozygous KCNK3 conditions, as they report function of
a substantial, discrete proportion of formed KCNK3 channels
in heterozygous patients. Fourth, mutant heterodimeric
KCNK3 channels can be pharmacologically targeted for
activation, dependent on the mutation. Fifth, KCNK9 co-
expression and assembly with KCNK3 channels protect
against KCNK3 dysfunction, which we hypothesize con-
tributes to the lung-specific phenotype observed clinically in
patients with PAH-associated heterozygous KCNK3 mutation.
A Unique pH-Dependent Mechanism of Mutant
KCNK3 Channel Dysfunction in PAH
Potassium channel mutations confer loss of function by
discrete mechanisms of varying severity. In well-studied
channelopathies, mechanisms of dysfunction include defects
in trafficking, channel assembly, and electrophysiological
function, dependent on the location of the mutation.27,28
In our study, V221L KCNK3 confers a pH-dependent
mechanism of loss of function. Extracellular histidine residues
lining the KCNK3 channel pore account for nearly all of the pH
sensitivity of KCNK3 directly, as protonation of these residues
leads to inhibition of potassium conductance.10,29 However,
other regions, including the extracellular portion of the fourth
transmembrane segment of KCNK3—the location of the V221
residue—may contribute to pH sensing and channel inhibition
indirectly by stabilizing the channel pore and the selectivity
filter within it.29,30 The unique properties of V221L KCNK3
can be exploited for KCNK3 structure–function studies in
relation to the channel’s crucial regulation by pH.
Mutant and WT KCNK3 Channels Are
Pharmacological Targets in hPASMCs
Potassium channels regulate the resting membrane potential
of pulmonary artery smooth muscle cells.31–33 Voltage-gated
potassium channels are involved in the hypoxic pulmonary
vasoconstrictive response,34 while downregulation of Kv
channel expression in PASMCs of PAH patients promotes
PASMC excitability and proliferation, and excessive pulmonary
arterial vasoconstriction.20,35,36 Potassium channel openers
may provide therapeutic benefit by opposing such deleterious
pulmonary arterial remodeling37; recently, pharmacological
KCNK3 activation by ONO-RS-082 (ONO) attenuated devel-
opment of pulmonary hypertension in a monocrotaline-
induced rat model.8
Figure 7. KCNK9 protects against KCNK3 dysfunction. A,
Quantitative real-time PCR analysis of human lung samples from
healthy (Control) and familial PAH (FPAH) patient lungs. Expres-
sion of KCNK3 (black bars), and KCNK9 (gray bars) are compared,
based on mean cycle threshold (Ct) values observed for each
gene; Ct>35 indicates no quantifiable gene expression (n=5
patient lungs for each lane). Of the possible KCNK3+KCNK9
channel combinations, only KCNK3 homomeric channels (boxed,
left) are predicted to form in human lungs. B, Voltage clamp
recordings of the WT-G203D KCNK3 heterodimer (left), and the
KCNK9-G203D KCNK3 heterodimer (right), showing current
traces at pH 6.4 (blue), 7.4 (black), and 10.4 (red). C, Summary
of current densities (pA/pF at 60 mV) at pH 6.4, 7.4, and 10.4
(n=4–14 cells per pH bar). Bar graphs show meanSEM. *P<0.05
by the unpaired Student t test. PAH indicates pulmonary arterial
hypertension; PCR, polymerase chain reaction; WT, wildtype.
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We therefore studied mutant and WT KCNK3 activation in
human PASMCs. KCNK3 expression is nearly completely lost
in cultured PASMCs, as a proliferative versus contractile
smooth muscle cell phenotype predominates concomitant
with loss of potassium channel expression and cell depolar-
ization.23 Previous studies have used anandamide and A293,
inhibitors of KCNK3 channel activity, to analyze the functional
contributions of KCNK3 on hPASMC excitability.8,9,38,39 We
confirmed loss of native KCNK3 channel activity in cultured
hPASMCs using a recently developed, more selective KCNK3
inhibitor, ML365 (Figure 2E through 2H and S1B).21
We exploited the properties of cultured hPASMCs to
compare the relative impact of expressed mutant versus WT
KCNK3 channels in a more physiological environment. The
current clamp results in Figure 3 demonstrate that (1) a
gradient exists for the relative contribution of mutant and WT
KCNK3 to the resting potential of hPASMCs, with cells
expressing mutant KCNK3 more depolarized at rest; and (2)
activation of mutant or WT KCNK3 by ONO hyperpolarizes
hPASMCs, highlighting PAH-associated mutant and WT
KCNK3 channels as viable pharmacological targets. Given
the overexpression of KCNK3 in our system, the results are
not meant to suggest that the magnitude of membrane
voltage responses is physiological, but rather provide proof of
principle for the graded responses of mutant and WT KCNK3
channels to pharmacologic activation in hPASMCs.
Based on the variable time course of activation of KCNK3
by ONO (seconds to minutes, not instantaneous), we hypoth-
esize that ONO does not bind directly to the channel. More
likely, ONO acts on membrane phospholipase pathways to
alter KCNK3 phosphorylation. It has been shown that
phospholipase C activation leads to KCNK3 inhibition,39 and
endothelin-1, a vasoconstrictor and mediator of PAH patho-
genesis, inhibits KCNK3 in hPASMCs leading to
Figure 8. Schematic of the proposed impact of heterozygous potassium channel subfamily K member 3
(KCNK3) mutation in pulmonary arterial hypertension (PAH). Wildtype KCNK3 (light blue) and mutant
(“PAH”) KCNK3 (dark blue) homomeric, and heterodimeric channels are expressed in human lung.
Additional interactions of KCNK3 with KCNK9 (brown) channel subunits occur outside of the lung,
protecting against KCNK3 loss of function. However, in human pulmonary artery smooth muscle cells
(hPASMCs), only KCNK3 (and not KCNK9) is expressed, and the greater proportion of mutant KCNK3
channels in hPASMCs promotes membrane depolarization. ONO-RS-082, a KCNK3 activator, recovers
function of some mutant and wildtype KCNK3 channels leading to PASMC hyperpolarization, which may
represent a therapeutic avenue in PAH. PAH indicates pulmonary arterial hypertension; PASMC, pulmonary
artery smooth muscle cell; WT, wildtype.
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depolarization, the sensitivity of which requires endothelin-A
receptors, phospholipase C, phosphatidylinositol 4,5-bispho-
sphate, diacylglycerol, and protein kinase C.40 Diacylglycerol
was recently identified as a direct regulator of KCNK3
downstream of activated G protein–coupled receptors.41
Ultimately, elucidating the specific pathways involved in
KCNK3 activation by ONO will further cultivate KCNK3
activation as a PAH treatment paradigm.42
Mutant KCNK3 Heterodimeric Channel Function
and Recovery
Mature KCNK3 channels dimerize, forming functional channels
from 2 individual KCNK3 subunits that co-assemble.10 In this
study, tandem-linked KCNK3 heterodimers served as a func-
tional reporter of a discrete and substantial population of
formed channels in heterozygous patients. The dominant-
negative phenotype conferred by the V221L KCNK3 mutation
did not prevent pharmacological recovery of function: hetero-
dimeric WTV221L KCNK3 channels responded to pharmaco-
logical activation by ONO. As KCNK3 downregulation occurs in
PAH irrespective of a patient’s KCNK3 genetic status,8 KCNK3
activation indeed represents a more generalizable therapeutic
approach in pulmonary hypertension from any cause.
While appreciable activation of homomeric mutant chan-
nels with marked loss of function at baseline was difficult to
discern, we have demonstrated robust current activation of
mutant heterodimeric KCNK3 channels by ONO (Figure 5; and
see Figure S2). Thus, in PAH patients heterozygous at the
KCNK3 gene locus, the majority of formed channels—WT
homodimeric and mutant heterodimeric KCNK3 channels—
may respond markedly to pharmacological activation and
represent targetable therapeutic substrates.
KCNK9 Minimizes the Impact of KCNK3 Loss of
Function
Interestingly, none of the PAH patients in our cohort with
heterozygous KCNK3 mutations possessed a primary clinical
phenotype outside of the lung, despite widespread KCNK3
expression in the body.4 KCNK9, which has been shown to
heterodimerize with KCNK3,11 is absent from human lungs of
healthy controls and PAH patients (Figure 7A; and see
Figure S3D and S3E), but assembles with KCNK3 in tissues
where both KCNK9 and KCNK3 are expressed, leading to
diversity of channel currents.12–14 We observed that KCNK9
heterodimerization with WT and G203D KCNK3 increased
current activity at physiological pH 7.4 compared with
equivalent KCNK3-only based channels, and suggest that
KCNK9 may protect against KCNK3 dysfunction.
We hypothesize that the co-expression of KCNK9 with
KCNK3 in tissues outside the lung provides redundancy of
channel function and protection against KCNK3 mutations of
varying severity, sparing tissues outside the lung of disease.
Meanwhile, the absence of KCNK9 in the lung would leave
PASMCs susceptible to excessive depolarization, proliferation,
and vasoconstriction in the setting of KCNK3 dysfunction.
Incomplete penetrance was observed in individuals with
PAH-associated KCNK3 mutations.3 Conceivably, KCNK9
provides greater protection in some individuals than others.
Some patients with heterozygous KCNK3 mutation may
develop PAH at a later age of onset, or not develop PAH at
all, dependent, in part, on KCNK9 channel activity.
Limitations
The impact of KCNK3 heterozygosity at the pulmonary arterial
level remains undetermined. Because of its altered pH
dependence easily discerned in electrophysiological studies,
the V221L KCNK3 mutation represents a model mutation to
incorporate into a rat model (eg, using CRISPR knock-in
technology) to recapitulate KCNK3 heterozygosity and eval-
uate the pathophysiological consequences in the lungs and
outside of them.8,43
Uncovering the cellular pathways involved in KCNK3
activation by ONO has broader implications than for PAH
pathogenesis and treatment alone. For instance, enhanced
KCNK3 activity was recently demonstrated in atrial myocytes
of patients with chronic atrial fibrillation, leading to shortening
of the action potential duration.44 Mechanistic understanding
of ONO’s regulation of KCNK3 would aid the development of
more selective pharmacological modulators of channel activity.
Conclusions
We have demonstrated, for the first time, that KCNK3
mutations associated with PAH harbor differing underlying
mechanisms of loss of function of varying severity; that
mutant KCNK3 channels represent viable therapeutic targets
in PAH via activation by ONO-RS-082 in pulmonary artery
smooth muscle cells; that engineered mutant heterodimeric
KCNK3 channels report function of a substantial proportion of
formed KCNK3 channels in heterozygous patients, and that
heterodimeric KCNK3 channels can be pharmacologically
activated; and lastly, that heterodimerization of KCNK9 with
KCNK3 can serve a protective role to minimize the impact of
heterozygous KCNK3 loss of function, which may underlie the
PAH-specific phenotype observed clinically in patients with
heterozygous KCNK3 mutation.
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Data S1.
Supplemental Methods 
Patients 
Human lung parenchymal samples were obtained from 10 control patients with healthy 
lungs (failed donor lungs); seven were female, three were male. Samples from patients 
with familial pulmonary arterial hypertension (FPAH) were obtained; three were female, 
two were male. Samples from patients with congenital cardiac defect -associated 
pulmonary arterial hypertension (APAH) were obtained; five patients were female. cDNA 
samples were provided by the Pulmonary Hypertension Breakthrough Initiative (PHBI).1 
The protocol, “Studying Gene Expression in Pulmonary Arterial and Lung Tissue in 
Healthy and Diseased Samples,” (#AAAQ2454) was approved by the Institutional Review 
Board at Columbia University Medical Center. KCNK3 mutations in PAH patients were 
identified as previously reported.2   
Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) 
The TaqMan gene expression system was used to quantify mRNA expression (Applied 
Biosystems). RNA and cDNA from lung samples were prepared for gene expression 
analysis using a previously described protocol.1 No-template controls lacking cDNA were 
included, to verify the specificity of the assay at recognizing cDNA templates of interest. 
Experiments were performed in duplicate for each sample. Data are expressed as means 
of the average cycle threshold (Ct) value of duplicates, and as fold changes in expression 
(2ddCt method). Commercially available assays from Applied Biosystems were used for 
priming/probing of cDNA samples, including:  
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1) KCNK3 (Assay ID= Hs00605529_m1)
2) KCNK9 (Assay ID= Hs00363153_m1)
3) GAPDH (Assay ID= Hs02758991_g1)
Expression of KCNK3 and KCNK9 in PAH and control lungs was normalized to GAPDH 
expression. Average cycle threshold (Ct) values at which signals for each gene appeared 
were calculated based on 40-cycle assays. For samples in which no amplification signal 
was produced, a Ct value of “40” was assigned for the purpose of calculating mean Ct 
values. 
Molecular Biology 
Mutations were engineered into human KCNK3 cDNA in a pcDNA3.1+ expression vector 
by site-directed mutagenesis using QuickChange (Stratagene).2 Human KCNK9 cDNA in 
a pIRES-GFP and pcDNA3.1+ vector was used. Where noted, KCNK3 constructs were 
tagged with a C-terminal green fluorescent protein (GFP). Tandem-linked KCNK3-
KCNK3 and KCNK9-KCNK3 dimer constructs were engineered by joining two KCNK 
subunits with a glycine-rich linker, and subcloned into a pcDNA3.1+ vector. 
Materials 
ONO-RS-082 (Enzo Life Sciences), ML365 (MedChem Express), and ruthenium red and 
DMSO (Life Technologies) were purchased commercially. ONO-RS-082 and ML365 were 
dissolved in DMSO and ruthenium red in water in 100mM stock solutions and stored at -
20°C. Drugs were diluted to 10µM in drug-containing external solutions, and DMSO 10µM 
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was added where appropriate to control (drug-free) solutions. Lipofectamine, 
Lipofectamine LTX, and Plus Reagent (Invitrogen) were used for transfection. 0.25% 
Trypsin/EDTA and Trypsin Neutralizer (Gibco) were used for splitting cell cultures. Human 
pulmonary artery smooth muscle cells (Gibco) were grown in Smooth Muscle Growth 
Medium-2 with supplements (SmGM-2 bulletkit, Lonza). COS7 cells (American Type 
Culture Collection) were cultured in medium containing DMEM 1X + GlutaMAX-1 with 
4.5g/L D-Glucose and 110mg/L Sodium Pyruvate (Gibco), and supplemented with 10% 
Fetal Bovine Serum (Gibco) and 1% Penicillin/Streptomycin (Gibco).   
Cell Culture and Heterologous Channel Expression 
KCNK3 and KCNK9 channel constructs were expressed in cultured hPASMC and COS7 
cell lines. GFP (in a pcDNA3.1+ vector) was co-expressed or tagged to the C-terminus of 
the channel as a marker of transfection. A previously established transfection protocol 
using Lipofectamine reagents was employed in COS7 cells,2 with modifications to 
optimize efficiency in hPASMCs. 
COS7 cells: 
On day 0, a T25 flask ~40-50% confluent was transfected with KCNK3 or KCNK9 cDNA 
using the following protocol: 2µg of KCNK3 or KCNK9 cDNA (20µl from a stock solution 
of 0.1µg/µl cDNA) + 1µg GFP if the KCNK3 construct was not GFP-tagged + 20µl PLUS 
reagent + OptiMEM medium supplemented with L-glutamine up to 200µl were mixed and 
incubated at room temperature for 20 minutes. Of note, for co-expression of two KCNK3 
(or KCNK3 + KCNK9) constructs, 1.5µg of each cDNA was transfected. 
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Next, 20µl Lipofectamine + 180µl OptiMEM medium supplemented with L-glutamine were 
added to the cocktail and incubated for 20 additional minutes at room temperature. Next, 
1.6ml of OptiMEM supplemented with L-glutamine was added to the cocktail and mixed, 
and the 2ml transfection cocktail was pipetted into the COS7 cell flask after removal of 
the culture medium. The flask was returned to the 37°C cell culture incubator 
(conventional growth conditions, 5% CO2) for approximately 4-6 hours. After incubation, 
the transfection cocktail was replaced by COS7 culture medium.  
On day 1 in the afternoon, cells transfected on day 0 were split into 10cm dishes in the 
culture hood as follows: culture medium was removed from the T25 flask, and 5ml of 1X 
PBS was quickly added and removed, before 2ml 0.25% Trypsin/EDTA was added to the 
flask. The flask was then placed back in the 37°C incubator for approximately 5 minutes. 
After cells were dislodged from the flask bottom, 5ml of cell medium was added to the 
flask and pipetted to dislodge more cells. The 7ml cell solution was pipetted out of the 
flask and transferred into a 15ml conical tube, and centrifuged for 1.5 minutes at 1xg. The 
conical tube was returned to the culture hood, medium removed, and new cell medium 
added for cell suspension. Cells were then pipetted into 10cm dishes, and placed back in 
the 37°C incubator. On day 2 (and day 3 if cells were still healthy), the 10cm dishes were 
used for patch clamp experiments.   
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Human Pulmonary Artery Smooth Muscle Cell Line: 
In hPASMCs, transfection of KCNK3 cDNA required the following protocol: On day 0, 
hPASMCs in a T25 flask were split into 10cm dishes suitable for patch clamp experiments. 
Cells were split using the manufacturer’s protocol (Gibco), which required 0.25% 
Trypsin/EDTA for cell detachment from the flask, and Trypsin Neutralizer to resuspend 
cells before plating in 10cm dishes. Cells were grown in supplemented Smooth Muscle 
Growth Medium-2 (Lonza). 
On day 1, cell were transfected under the culture hood, as follows: per 10cm dish, 0.6µg 
KCNK3 cDNA tagged with GFP at the C-terminus (from a cDNA stock solution of 0.1µg/µl) 
+ 0.6µl PLUS reagent + 50µl OptiMEM medium supplemented with L-glutamine, were
mixed and incubated at room temperature for 10 minutes. Next, 1.5µl Lipofectamine LTX 
per dish was added to the cocktail and incubated for an additional 30 minutes at room 
temperature. Equal proportions (58.1µl) of the cocktail were then pipetted into each 10cm 
dish, and dishes were returned to the 37°C incubator. On day 2 (and day 3 if cells were 
still healthy), 10cm dishes were used for patch clamp experiments.  
Electrophysiology 
KCNK3 channel current and membrane potential changes were recorded by whole-cell 
patch clamp in hPASMCs and COS7 cells. An Axopatch 200B amplifier (Axon 
Instruments), Digidata 1440A model, and pClamp 10 software were used for recording 
and analysis (Molecular Devices, CA). Pipette resistances generally ranged from 1-4 
MOhm. For all voltage clamp experiments, cells were held at -80mV and a 500ms voltage 
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ramp was applied once every 3 seconds, with voltage increasing linearly from -120mV to 
+60mV before returning to holding. Expressed KCNK3, KCNK9, and tandem dimer
constructs were recorded. For current clamp experiments, changes in membrane 
potential were recorded over time after first applying the voltage ramp to verify stability of 
the patch and expression of KCNK3 channels. 
Perfusion of extracellular solutions containing pharmacological agents or different pH 
values occurred at recorded intervals during patch clamp experiments, at room 
temperature under normoxic conditions. All experiments with pharmacological agents 
were conducted at extracellular pH 7.4.  
For experiments in COS7 cells, solutions were prepared as previously reported 2:  pipette 
(internal) solution (in mmol/L) contained: 150 KCl, 3 MgCl2, 5 EGTA, 10 HEPES, adjusted 
to pH 7.2 with KOH. Bath (extracellular) solution (in mmol/L) contained: 150 NaCl, 5 KCl, 
1 MgCl2, 1.8 CaCl2, 10 HEPES adjusted to pH 6.4, 7.4, or 8.4 with NaOH.  
For experiments in hPASMCs, solutions were adapted from a previous study:3 pipette 
(internal) solution (in mmol/L) contained: 135 K-methanesulphonate, 20 KCl, 2 Na2ATP, 
1 MgCl2, 1 EGTA, 20 HEPES, adjusted to pH 7.2 with KOH.  Bath (extracellular) solution 
(in mmol/L) contained: 140.5 NaCl, 5.5 KCl, 1.5 CaCl2, 1 MgCl2, 10 glucose, 0.5 
Na2HPO4, 0.5 KH2PO4, 10 HEPES, adjusted to pH 6.4, 7.4, or 8.4 with NaOH.  
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In COS7 cells and hPASMCs, solutions at pH 5.0 contained 10 mmol/L 2-(N-
morpholino)ethane sulfonic acid instead of HEPES. Solutions at pH 10.4 contained 10 
mmol/L Tris-Base instead of HEPES.  
Voltage Clamp Analysis 
Cell capacitance values were recorded for individual cell recordings, and whole cell 
currents were normalized to cell capacitance (pA/pF) where indicated. Measurements of 
current for drug analysis (ONO-RS-082, ML365, and ruthenium red) were taken at -50mV 
to minimize contributions from background cellular ionic currents. This was performed by 
taking the mean current at -50mV over an approximately 5 millisecond range centered 
around -50mV, from the average of 2 to 6 consecutive traces based on stability of the 
recording. Measurements of current were taken at +60mV for pH experiments (as 
previously shown in 2), by calculating the mean current during the last ~5 milliseconds of 
the trace, based on the average of 2 to 6 consecutive traces depending on stability of the 
recording at each pH value.  
Leak subtraction was manually performed on all recordings in this study. Based on the 
Nernst equilibrium potential for potassium (EK) close to -80mV, negative current values 
recorded at the holding potential of -80mV were designated as leak current, and a 
proportional amount of leak current was extrapolated across the voltage ramp range; an 
assumption applied for analysis given the virtually voltage-independent properties of the 
KCNK3 and KCNK9 channels. Hence, analysis of mean current in any drug condition at 
-50mV required adding 5/8 of the value of the leak current at -80mV to the mean current
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value recorded at -50mV, and analysis of mean current at +60mV required subtracting 
6/8 of the value of the leak current at -80mV from the mean current value recorded at 
+60mV.
Current Clamp Analysis 
Measurements of membrane potential were taken as the mean from the last ~10 seconds 
in any given pH or drug condition. To standardize drug analysis, all ONO membrane 
potential measurements were taken from the last ~10 seconds of five minutes of ONO 
application, and all ONO+ML365 membrane potential measurements were taken from 
the last ~10 seconds of two minutes of ONO+ML365 co-application. Using pClamp 
software, a 50X data reduction of recordings was performed for data transfer compatibility 
to Origin for figure purposes. Data analysis was performed on raw data only. 
Statistical Analyses 
Graphic analysis was performed with Origin 7.0 and 9.0 (Microcal Software, Northampton, 
MA). pClamp 10 software was used for analysis of raw electrophysiological recordings. 
Data are reported as means ± SEM, based on n observations. Student’s t tests and one-
way ANOVA with post-hoc Tukey tests were applied as indicated, and significant 
differences were determined based on p < 0.05. Statistical tests were performed using 
Origin and Excel (Microsoft, Bellevue, WA) software.  
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Supplemental Figure Legends:
Figure S 1.  KCNK3-GFP expression and activity in hPASMCs. A, Summary of 
current clamp results of KCNK3-GFP expressed in hPASMCs, with mean membrane 
potentials (mV) measured at pH 6.4 (blue), pH 7.4 (black), and pH 10.4 (red) shown 
(n=2 to 4 cells per pH value). B, Comparison of the ML365-sensitive current (pA/pF at 
-50mV, pH 7.4), in hPASMCs expressing KCNK3-GFP (n=3 cells) versus no 
transfection (n=6 cells). C, Gradient of current expression (pA/pF at 60mV, pH 7.4) in 
hPASMCs expressing KCNK3-GFP (n=20 cells), V221L KCNK3-GFP (n=7 cells), and 
GFP only (n=3 cells). D, Sample current trace of V221L KCNK3-GFP in hPASMC at pH 
7.4 (black) and pH 8.4 (red). E, Summary of V221L KCNK3 expression in COS7 cells 
versus V221L KCNK3-GFP expression in hPASMCs (n=4 to 7 cells per lane), showing 
greater current activity of expressed channels in hPASMCs (pA/pF at 60mV, pH 7.4 in 
black, pH 8.4 in red). Data are represented as means ± SEM. * indicates p<0.05 by the 
unpaired Student’s t test.   
Figure S 2. ONO-RS-082’s effect on homomeric and heterodimeric mutant 
KCNK3 channels associated with PAH. Voltage clamp recordings in COS7 cells 
are depicted. A-D, The effect of ONO-RS-082 10 µM (red traces) at extracellular pH 7.4 
on currents from cells expressing T8K KCNK3 (A); V221L KCNK3 (B); E182K KCNK3 
(C); and heterodimeric WT-E182K KCNK3 (D). Control (pre-drug) conditions at 
extracellular pH 7.4 (black traces) are shown for each recording.  
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Figure S3. The impact of KCNK9 expression and current activity on KCNK3 
function. A, The effect of ruthenium red (RR) 10 µM (red trace) on KCNK3 
channels in COS7 cells is shown. Control trace (pre-drug, pH 7.4) is depicted in grey. B, 
Sample RR time course of action on KCNK3 in control and drug conditions, measured at 
-50mV, from a starting current amplitude of 196 pA indicated by the arrow. C, RR’s effect 
on KCNK9, KCNK3, and KCNK9-KCNK3 channels is summarized, showing fold change 
in current at -50mV (n=5 to 8 cells per condition). D, Quantitative real-time PCR analysis 
of human lung samples from healthy (Control) and congenital cardiac defect-associated 
PAH (APAH) patient lungs. Expression of KCNK3 (black bars), and KCNK9 (grey bars) 
are compared, based on mean cycle threshold (Ct) values observed for each gene; Ct > 
35 indicates no quantifiable gene expression (n=5 patient lungs for each lane). Bars 
shown mean ± SEM. E, Fold difference in KCNK3 gene expression, calculated by the 2-
ddCt method, in FPAH and APAH versus Control patient lungs. No significant (N.S.) fold 
changes were observed compared to control. F-G, Co-expression of KCNK9 with WT 
KCNK3 channels (panel F), and KCNK9 with V221L KCNK3 channels (panel G) with 
sample voltage clamp recordings shown for each condition at pH 6.4 (blue), pH 7.4 (black) 
and pH 10.4 (red). H, Summary of current activity for co-expression of KCNK9 with WT 
KCNK3 (left) versus V221L KCNK3 (right). Current at pH 6.4 (blue) and pH 7.4 (black) is 
normalized to max current at pH 10.4 (n=5 to 8 cells per lane). Experiments were 
performed in COS7 cells. Bar graphs show mean ± SEM. * indicates p<0.05 by the paired 
Student’s t test for the comparison of control versus ruthenium red conditions in panel C; 
* indicates p<0.05 by the unpaired Student’s t test in panel H.
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Figure S4. KCNK3 heterodimeric GFP fusion dimer confirms the more severe loss 
of function in G203D versus V221L-containing KCNK3 channels. A, A WT-G203D 
KCNK3-GFP fusion heterodimer was engineered by interconnecting two KCNK3 
subunits with a glycine-rich linker, and inserting a C-terminal GFP tag. Given the relative 
severity of G203D KCNK3 dysfunction, the GFP fusion construct ensured channel 
expression in fluorescent cells studied. Sample traces from a voltage clamp recording are 
shown at extracellular pH 5 (blue), pH 7.4 (black), and pH 10.4 (red), revealing small 
currents across the pH range. B, Summary of current densities (pA/pF at 60mV) at pH 5 
(blue), pH 7.4 (black), and pH 10.4 (red) for the WT-V221L KCNK3 heterodimer versus 
the WT-G203D KCNK3-GFP heterodimer (n= 6 to 16 cells per pH bar). Bars show mean 
± SEM. * indicates p<0.05 at pH 7.4 and pH 10.4, by the unpaired Student’s t test.  
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Supplemental Figures 
Figure S1. 
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